Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Genemedicine Co. Ltd. has 2 pending office actions distributed across the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners located in a pair of distinct art units. This distribution indicates that each pending matter is being reviewed by a different individual in separate administrative divisions, which may lead to independent prosecution timelines for each application.
The busiest examiner identified in the data is Moloye, Titilayo, who is overseeing 1 pending office action. This represents a single portion of the total pending office actions currently active for the company. With a single examiner assigned to each case, the prosecution remains decentralized across the separate units, requiring the company to manage distinct examiner preferences and art unit specific trends. This lack of concentration means that the outcome of a matter is less likely to directly influence the examiner's perspective on the other pending application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOLOYE, TITILAYO | 1 | 62.3% | +48.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18955792 | ANTICANCER COMPOSITION COMPRISING RECOMBINANT ADENOVIRUS EXPRESSING DEGRADATION FACTOR FOR EXTRACELLULAR MATRIX | MOLOYE, TITILAYO | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18955792 | ANTICANCER COMPOSITION COMPRISING RECOMBINANT ADENOVIRUS EXPRESSING DEGRADATION FACTOR FOR EXTRACELLULAR MATRIX | MOLOYE, TITILAYO | 1632 | §103 | Non-Final OA | — | Pending | Nov 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenemedicine Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Titilayo Moloye has the most, with 1 of Genemedicine Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
